219 related articles for article (PubMed ID: 36562643)
1. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co-infection.
Lodi S; Klein M; Rauch A; Epstein R; Wittkop L; Logan R; Rentsch CT; Justice AC; Touloumi G; Berenguer J; Jarrin I; Egger M; Puoti M; D'Arminio Monforte A; Gill J; Salmon Ceron D; van Sighem A; Linas B; van der Valk M; Hernán MA;
J Int AIDS Soc; 2022 Dec; 25(12):e26048. PubMed ID: 36562643
[TBL] [Abstract][Full Text] [Related]
2. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
[TBL] [Abstract][Full Text] [Related]
3. CD4+ T-cell recovery in HIV/hepatitis C co-infected patients following successful hepatitis C treatment.
Ryscavage P; Hussien S; Seung H; Hynicka L
HIV Med; 2024 May; 25(5):622-627. PubMed ID: 38273652
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection.
Domínguez-Domínguez L; Bisbal O; Matarranz M; Lagarde M; Pinar Ó; Hernando A; Lumbreras C; Rubio R; Pulido F
Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):725-734. PubMed ID: 30687869
[TBL] [Abstract][Full Text] [Related]
5. Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.
d'Arminio Monforte A; Cozzi-Lepri A; Ceccherini-Silberstein F; De Luca A; Lo Caputo S; Castagna A; Mussini C; Cingolani A; Tavelli A; Shanyinde M; Gori A; Girardi E; Andreoni M; Antinori A; Puoti M;
PLoS One; 2017; 12(5):e0177402. PubMed ID: 28520749
[TBL] [Abstract][Full Text] [Related]
6. Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.
Kronfli N; Nitulescu R; Cox J; Moodie EE; Wong A; Cooper C; Gill J; Walmsley S; Martel-Laferrière V; Hull MW; Klein MB;
J Int AIDS Soc; 2018 Nov; 21(11):e25197. PubMed ID: 30460791
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
Bhattacharya D; Belperio PS; Shahoumian TA; Loomis TP; Goetz MB; Mole LA; Backus LI
Clin Infect Dis; 2017 Jun; 64(12):1711-1720. PubMed ID: 28199525
[TBL] [Abstract][Full Text] [Related]
8. Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy.
Mandorfer M; Neukam K; Rivero A; Puoti M; Boesecke C; Baumgarten A; Grzeszczuk A; Zangerle R; Ernst D; Rockstroh JK; Trauner M; Pineda JA; Peck-Radosavljevic M; Reiberger T
Antivir Ther; 2014; 19(4):407-14. PubMed ID: 24342953
[TBL] [Abstract][Full Text] [Related]
9. Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018.
Simoncini GM; Hou Q; Carlson K; Buchacz K; Tedaldi E; Palella F; Durham M; Li J;
AIDS Patient Care STDS; 2021 Oct; 35(10):392-400. PubMed ID: 34623891
[TBL] [Abstract][Full Text] [Related]
10. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.
Piroth L; Wittkop L; Lacombe K; Rosenthal E; Gilbert C; Miailhes P; Carrieri P; Chas J; Poizot-Martin I; Gervais A; Dominguez S; Neau D; Zucman D; Billaud E; Morlat P; Aumaitre H; Lascoux-Combe C; Simon A; Bouchaud O; Teicher E; Bani-Sadr F; Alric L; Vittecoq D; Boué F; Duvivier C; Valantin MA; Esterle L; Dabis F; Sogni P; Salmon D;
J Hepatol; 2017 Jul; 67(1):23-31. PubMed ID: 28235612
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
[TBL] [Abstract][Full Text] [Related]
13. Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals.
Berenguer J; Gil-Martin Á; Jarrin I; Montes ML; Domínguez L; Aldámiz-Echevarría T; Téllez MJ; Santos I; Troya J; Losa JE; Serrano R; De Guzmán MT; Calvo MJ; González-García JJ;
AIDS; 2019 Mar; 33(4):685-689. PubMed ID: 30829744
[TBL] [Abstract][Full Text] [Related]
14. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
[TBL] [Abstract][Full Text] [Related]
15. Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants.
Chalouni M; Wittkop L; Bani-Sadr F; Lacombe K; Esterle L; Gilbert C; Miailhes P; Zucman D; Valantin MA; Brégigeon-Ronot S; Morlat P; Billaud E; Piroth L; Naqvi A; Sogni P; Salmon D;
HIV Med; 2021 Oct; 22(9):791-804. PubMed ID: 34212476
[TBL] [Abstract][Full Text] [Related]
16. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.
Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA
Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695
[TBL] [Abstract][Full Text] [Related]
17. Impact of hepatitis C cure on risk of mortality and morbidity in people with HIV after antiretroviral therapy initiation.
Chalouni M; Trickey A; Ingle SM; Sepuvelda MA; Gonzalez J; Rauch A; Crane HM; Gill MJ; Rebeiro PF; Rockstroh JK; Franco RA; Touloumi G; Neau D; Laguno M; Rappold M; Smit C; Sterne JAC; Wittkop L;
AIDS; 2023 Aug; 37(10):1573-1581. PubMed ID: 37199601
[TBL] [Abstract][Full Text] [Related]
18. Liver Stiffness-Based Strategies Predict Absence of Variceal Bleeding in Cirrhotic Hepatitis C Virus-Infected Patients With and Without Human Immunodeficiency Virus Coinfection After Sustained Virological Response.
Corma-Gómez A; Macías J; Morano L; Rivero A; Téllez F; Ríos MJ; Santos M; Serrano M; Palacios R; Merino D; Real LM; De Los Santos I; Vera-Méndez FJ; Galindo MJ; Pineda JA;
Clin Infect Dis; 2021 Mar; 72(5):e96-e102. PubMed ID: 33211801
[TBL] [Abstract][Full Text] [Related]
19. Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada.
Marathe G; Moodie EEM; Brouillette MJ; Lanièce Delaunay C; Cox J; Martel-Laferrière V; Gill J; Cooper C; Pick N; Vachon ML; Walmsley S; Klein MB;
Clin Infect Dis; 2023 Feb; 76(3):e702-e709. PubMed ID: 35789253
[TBL] [Abstract][Full Text] [Related]
20. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
